Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the addition of cetuximab to pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma after prior thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING